AMBRA1 and neuropathy: In non-fasted animals glycemia (main treatment effect F1,1 = 8,37 p .009; main effect–time F2,20 = 6,31 p .004; treatment*time F2,2 = 6,3 p .004) was altered by the neuropathy induction, decreasing 24h after CCI in WT ST mice (WT ST vs WT BL; p < .05 Tukey HSD) and at 7 days in Ambra1 ST mice (A+/- ST vs A+/- BL, p < .05 Tukey HSD) as compared to the BL condition.